Therapeutic Goods Regulations (Amendment)

Overview

Statutory Rules 1979 No. 135, issued under the Therapeutic Goods Act 1966, were enacted to amend the Therapeutic Goods Regulations. The primary purpose of these regulations was to update the membership and appointment processes of the Therapeutic Goods Advisory Committee and the Therapeutic Goods Standards Committee, ensuring that they remain effective and representative of the relevant stakeholders. The regulations were made by the Governor-General, acting on the advice of the Federal Executive Council, and reflect the policy objective of maintaining robust oversight and expert input into the regulation of therapeutic goods in Australia. This legislative instrument aims to improve the governance and advisory structures for therapeutic goods by enhancing the inclusivity and responsiveness of the relevant committees.

Scope and Application

The Therapeutic Goods Regulations, made under the Therapeutic Goods Act 1966, apply to the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood and blood components. The regulations cover a wide range of entities, including manufacturers, importers, and suppliers of therapeutic goods. They establish standards and requirements for the approval, registration, and monitoring of these goods to ensure their safety, quality, and efficacy. The regulations also outline the composition and responsibilities of committees such as the Therapeutic Goods Advisory Committee and the Therapeutic Goods Standards Committee, which provide expert advice to the Minister of Health on various aspects of therapeutic goods regulation. The geographic reach of these regulations is national, applying across all states and territories of Australia. Certain exclusions and exemptions may apply, such as for therapeutic goods used for personal or non-commercial purposes. The regulations can be extended or modified through subordinate instruments, enabling the Minister to adapt the regulatory framework in response to emerging issues and advancements in therapeutic goods.

Key Provisions

The Regulations under the Therapeutic Goods Act 1966 introduce several amendments primarily affecting the composition and functioning of the Therapeutic Goods Advisory Committee and the Therapeutic Goods Standards Committee. Regulation 17 has been amended to include a new member from The Australian Federation of Consumer Organizations Incorporated (Regulation 17(2)(i)), with the flexibility to replace a member unable to attend meetings with an alternate nominee (Regulation 17(5)). Additionally, Regulation 18 has been modified to replace the Pharmaceutical Association of Australia and New Zealand with the Pharmaceutical Society of Australia (Regulation 18(2)(d)), and to specify that the alternate nominee in this case is to be appointed by the Pharmaceutical Society of Australia (Regulation 18(6)(a)). These changes impose specific obligations on the Therapeutic Goods Advisory Committee and the Therapeutic Goods Standards Committee, including the requirement to include a member from The Australian Federation of Consumer Organizations Incorporated and an alternate member provision in case of absence. For the Therapeutic Goods Standards Committee, the regulations necessitate the replacement of the Pharmaceutical Association of Australia and New Zealand with the Pharmaceutical Society of Australia and clarify the process for appointing an alternate member in the event of a member's absence. There are no explicit provisions detailing offences, penalties, or consequences for breach within the text of the Regulations. However, given the legislative context, it can be inferred that failure to comply with the provisions may result in regulatory actions under the Therapeutic Goods Act 1966, which could include fines or other penalties as stipulated by the broader legislative framework. The maximum penalties would be determined by the Therapeutic Goods Act 1966 and the specific nature of the breach.